Kalra Balkrishan

CEO Balkrishan sells 55,000 shares at $43.36–$43.39 for $2.4M, reducing stake by 15.7%

Kalra Balkrishan, President and CEO of Genpact, executed 2 separate sales totaling 55,000 shares for $2,384,850.00 at a blended average price of $43.36, reducing his post-transaction holdings to 295,246 shares from 350,246 shares. The sales occurred as the stock trades at $42.11, down 24.2% from its 52-week high of $55.54. Balkrishan's prior 2 sells at Genpact generated a 90-day return of -10.3% (March 2025) and +10.6% (December 2024), with 1 of 2 well-timed at the 90-day mark. This sale represents a meaningful reduction in executive exposure at a depressed valuation relative to recent highs, following a pattern of occasional equity reductions at this ticker.

Genpact CEO Kalra sells 13,600 shares at $48.89 for $664.9K; retains 310.2K shares post-sale

CEO Balkrishan Kalra sold 13,600 shares at $48.89, reducing his stake by 4.2% to 310.2K shares. The transaction occurred at a price -9.7% below the 52-week high of $55.54 and follows a 30-day decline of -8.7%, though the stock is up +12.2% over the prior 90 days. Looking at his prior sell at this ticker on 2024-12-13, that trade yielded a 90-day return of +10.6%, meaning the stock rose after he sold—timing that was not well-timed from a risk-avoidance perspective. With Genpact trading at a P/E of 16.12 and generating +6.5% annual revenue growth on a $1.2B revenue base, the company shows stable fundamentals; the sale itself represents a discrete reduction in his exposure without material change to overall holdings structure.

Genpact CEO Kalra sold 13,600 shares at $44.60 (12/13/2024), reducing holdings by 4.8%; stock now at $43.27

Kalra Balkrishan, President and CEO of Genpact, sold 13,600 shares for $606,560.00 on 2024-12-13 at $44.60 per share, leaving him with 267,404 shares post-transaction. The sale reduced his holdings by 4.8% relative to his pre-transaction position of 281,004 shares. At the current price of $43.27, the stock trades 7.6% below its 52-week high of $46.82 and has declined 3.4% over the past 30 days, though it is up 12.9% over 90 days. With a P/E of 11.51, $1.2B in latest quarterly revenue, and modest 2.4% annual revenue growth, the company operates in a low-growth environment. The transaction reflects a discrete reduction of executive equity position but remains modest in absolute scale relative to the CEO's substantial remaining stake of 267,404 shares.